This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (41)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Multiple Sclerosis/ Demyelinating Disease  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Arnon Karni, MD; Ronit Bakimer-Kleiner, PhD; Oded Abramsky, MD, PhD; Avraham Ben-Nun, PhD

Arch Neurol. 1999;56:311-315.

Objective  To evaluate the presence and specificity of anti–myelin oligodendrocyte glycoprotein (MOG) antibody in the cerebrospinal fluid and plasma of patients with multiple sclerosis (MS).

Design  Case-control study of patients with clinically definite MS compared with patients with other neurologic diseases (ONDs) of the central nervous system and control subjects.

Setting  Referral center in the Department of Neurology of Hadassah University Hospital, greater Jerusalem area, Israel.

Participants  Consecutive cerebrospinal fluid samples from 31 patients with MS, 31 patients with ONDs, and 28 healthy controls; and plasma samples from 33 patients with MS, 28 patients with ONDs, and 31 healthy controls were taken from the cerebrospinal fluid and plasma bank of the Department of Neurology, Hadassah University Hospital.

Main Outcome Measures  Levels and frequencies of anti-MOG antibody in patients with MS, as defined by enzyme-linked immunosorbent assay.

Results  Cerebrospinal fluid levels of antibodies to MOG and to myelin basic protein were significantly higher in patients with MS (P<.001 and P=.001, respectively) and patients with ONDs (P=.005 and P=.03, respectively) compared with controls; frequency of antibodies to MOG, but not to myelin basic protein, was higher in patients with MS and patients with ONDs (P=.01 and P=.003, respectively, for the frequency of anti-MOG antibody, and P=.65 and P=.41, respectively, for the frequency of anti-myelin basic protein antibody). Plasma levels of antibodies to MOG and to myelin basic protein were higher in patients with MS compared with patients with ONDs (P=.003 for both comparisons) and with controls (P=.03 and P=.04, respectively); however, the frequency of antibodies to MOG and myelin basic protein was similar in patients with MS, patients with ONDs (P=.54 and P=.82, respectively), and controls (P=.50 and P=.14, respectively).

Conclusions  The elevated presence of anti-MOG antibody is not specific for MS because a similar appearance was also demonstrated in patients with ONDs. Therefore, it is not clear whether this antibody is pathogenic in MS or, on the contrary, has a defensive role against further immune-mediated damage after myelin breakdown.

From the Department of Neurology, Hadassah University Hospital, Hebrew University Hadassah Medical School, Jerusalem (Drs Karni and Abramsky), and the Department of Immunology, The Weizmann Institute of Science, Rehovot (Drs Bakimer-Kleiner and Ben-Nun), Israel.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(3):370-371.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis
Vogt et al.
J. Neurol. Neurosurg. Psychiatry 2009;80:1110-1115.
ABSTRACT | FULL TEXT  

Autoantibody Profiling in Multiple Sclerosis Reveals Novel Antigenic Candidates
Somers et al.
J. Immunol. 2008;180:3957-3963.
ABSTRACT | FULL TEXT  

Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations
Pittock et al.
Mult Scler 2007;13:7-16.
ABSTRACT  

Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event.
Rauer et al.
J. Neurol. Neurosurg. Psychiatry 2006;77:739-742.
ABSTRACT | FULL TEXT  

Antibodies from Inflamed Central Nervous System Tissue Recognize Myelin Oligodendrocyte Glycoprotein
O'Connor et al.
J. Immunol. 2005;175:1974-1982.
ABSTRACT | FULL TEXT  

Methodologic Factors Affect the Measurement of Anti-basal Ganglia Antibodies
Rippel et al.
Annals of Clinical & Laboratory Science 2005;35:121-130.
ABSTRACT | FULL TEXT  

Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association
Mantegazza et al.
Int Immunol 2004;16:559-565.
ABSTRACT | FULL TEXT  

Antibody Cross-Reactivity between Myelin Oligodendrocyte Glycoprotein and the Milk Protein Butyrophilin in Multiple Sclerosis
Guggenmos et al.
J. Immunol. 2004;172:661-668.
ABSTRACT | FULL TEXT  

Activity profile in multiple sclerosis: an integrative approach A preliminary report
Zabaleta et al.
Mult Scler 2002;8:343-349.
ABSTRACT  

Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination
von Budingen et al.
Proc. Natl. Acad. Sci. USA 2002;99:8207-8212.
ABSTRACT | FULL TEXT  

Antigen Discovery in Chronic Human Inflammatory Central Nervous System Disease: Panning Phage-Displayed Antigen Libraries Identifies the Targets of Central Nervous System-Derived IgG in Subacute Sclerosing Panencephalitis
Burgoon et al.
J. Immunol. 2001;167:6009-6014.
ABSTRACT | FULL TEXT  

Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination-possible markers for an antibody-mediated process
Bruck et al.
Mult Scler 2001;7:173-177.
ABSTRACT  

Anti-DNA antibodies are a major component of the intrathecal B cell response in multiple sclerosis
Williamson et al.
Proc. Natl. Acad. Sci. USA 2001;98:1793-1798.
ABSTRACT | FULL TEXT